Xanomeline
≥95%
- Product Code: 51921
CAS:
131986-45-3
| Molecular Weight: | 281.42 g./mol | Molecular Formula: | C₁₄H₂₃N₃OS |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD00867179 | |
| Melting Point: | Boiling Point: | 397°C at 760 mmHg | |
| Density: | Storage Condition: | 2-8°C, dry and sealed |
Product Description:
Xanomeline is primarily investigated for its potential therapeutic applications in neurological disorders, particularly Alzheimer's disease and schizophrenia. It acts as a muscarinic acetylcholine receptor agonist, targeting M1 and M4 subtypes, which are involved in cognitive and behavioral functions. In clinical trials, it has shown promise in improving cognitive performance and reducing psychotic symptoms, such as hallucinations and delusions, in patients with Alzheimer's disease. Additionally, its role in enhancing memory and learning processes makes it a candidate for treating cognitive deficits associated with schizophrenia. However, its use is often limited by side effects like gastrointestinal disturbances and excessive sweating, prompting ongoing research to develop more selective analogs or improved delivery methods.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | Orange to yellow powder or solid |
| PURITY | 94.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $275.28 |
+
-
|
| 0.025 | 10-20 days | $825.85 |
+
-
|
| 0.100 | 10-20 days | $2,359.56 |
+
-
|
| 0.250 | 10-20 days | $4,373.05 |
+
-
|
Xanomeline
Xanomeline is primarily investigated for its potential therapeutic applications in neurological disorders, particularly Alzheimer's disease and schizophrenia. It acts as a muscarinic acetylcholine receptor agonist, targeting M1 and M4 subtypes, which are involved in cognitive and behavioral functions. In clinical trials, it has shown promise in improving cognitive performance and reducing psychotic symptoms, such as hallucinations and delusions, in patients with Alzheimer's disease. Additionally, its role in enhancing memory and learning processes makes it a candidate for treating cognitive deficits associated with schizophrenia. However, its use is often limited by side effects like gastrointestinal disturbances and excessive sweating, prompting ongoing research to develop more selective analogs or improved delivery methods.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :